Digital Health 150 lists most promising healthcare startups

There are a trove of new companies breaking into the healthcare space with new and innovative solutions. And many of these are well-funded to the tune of several million dollars through venture capital funding.

CB Insights listed 150 of the “most promising private companies” with new products and services in the healthcare space with its first-ever Digital Health 150. The companies were chosen from a pool of more than 5,000 and were assessed on several factors, such as patent activity, investor profile, sentiment analysis, market potential, tech novelty and more.

The group represents $17.5 billion in funding from more than 500 equity deals. The funding came from over 850 unique investors, with F-Prime Capital, New Enterprise Associates and Google Ventures being the most active investors. Of the selected companies, 116 were located in the U.S., while 17 were from Asia, 16 from Europe and 1 from Canada.

The most well-funded companies include:

  • Grail, a biotech company that seeks to detect cancer early––$1.6 billion in funding
  • Oscar Health, a tech-focused health insurance provider––$1.27 billion
  • We Doctor, a China-based tech-enabled healthcare solutions platform––$1 billion
  • 23andMe––$791 million
  • Babylon Health––$635 million
  • HeartFlow––$532 million
  • Tempus––$520 million
  • American Well––$507 million
  • Proteus Digital Health––$474 million
  • Bright Health––$440 million

See the full Digital Health 150 here.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

“Now more than ever, we must recognize that our country’s leadership in groundbreaking medical research spurs scientific innovation, improves public health and creates new innovations that save and improve lives nationwide,” Joseph C. Wu, MD, PhD, explained in a statement. 

The technology used to diagnose, treat and manage cardiovascular disease is always evolving, keeping FDA officials quite busy. But have the agency's standards been slipping in recent years? A cardiologist with Cedars-Sinai Medical Center explored that very question.

No devices need to be returned at this time. However, the FDA warned, using these heart pumps without reviewing the updated instructions could result in "serious injury or death.”